Oncotype DX Breast Recurrence Score

Last revised by Mohamed Saber on 6 Dec 2023

Citation, DOI, disclosures and article data

Citation:

Tafti D, Saber M, Knipe H, Oncotype DX Breast Recurrence Score. Reference article, Radiopaedia.org (Accessed on 09 May 2024) https://doi.org/10.53347/rID-179125

DOI:

https://doi.org/10.53347/rID-179125

Permalink:

https://radiopaedia.org/articles/179125

rID:

179125

Article created:

27 Nov 2023, Dawood Tafti

Disclosures:

At the time the article was created Dawood Tafti had no financial relationships to ineligible companies to disclose.

View Dawood Tafti's current disclosures

Last revised:

6 Dec 2023, Mohamed Saber ◉

Disclosures:

At the time the article was last revised Mohamed Saber had no financial relationships to ineligible companies to disclose.

View Mohamed Saber's current disclosures

Revisions:

3 times, by 3 contributors - see full revision history and disclosures

Systems:

Breast

Sections:

Pathology

Tags:

refs, cases

Oncotype DX Breast Recurrence Score (Exact Sciences, USA) is a proprietary 21-gene expression assay that is prospectively validated and provides prognostic information on the 10-year risk of disease recurrence in estrogen receptor positive, lymph node-negative breast cancer patients ¹. This gene assay predicts chemotherapy benefit in patients with favorable gene-expression profiles conferring a low rate of recurrence at 5 years. A score of 0 to 100 conveys a high rate of freedom of recurrence at a distant or locoregional site of disease ².